We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-1.74%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$2.74B
AUM Growth
+$339M
Cap. Flow
-$310M
Cap. Flow %
-11.3%
Top 10 Hldgs %
45.15%
Holding
404
New
120
Increased
93
Reduced
80
Closed
88

Top Buys

Rank Stock Value
1
TLT icon
iShares 20+ Year Treasury Bond ETF
TLT
+$23.4M
2
XOM icon
ExxonMobil
XOM
+$15.3M
3
PXD
Pioneer Natural Resource Co.
PXD
+$12.1M
4
MRK icon
Merck
MRK
+$9.03M
5
BPMC
Blueprint Medicines
BPMC
+$8.62M

Top Sells

Rank Stock Value
1
TPST icon
Tempest Therapeutics
TPST
+$53.9M
2
AGN
Allergan plc
AGN
+$33.8M
3
IWM icon
iShares Russell 2000 ETF
IWM
+$24.7M
4
MBLY
Mobileye N.V.
MBLY
+$7.21M
5
MNKD icon
MannKind Corp
MNKD
+$5.7M

Sector Composition

Rank Sector Weight
1 Healthcare 8.27%
2 Energy 1.27%
3 Technology 0.21%
4 Communication Services 0.15%
5 Industrials 0.12%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CEMP
176
CALL
DELISTED
Cempra, Inc.
CEMP
$1.72M 0.06%
501
+116
+30% +$4.1K
ELDN icon
177
Eledon Pharmaceuticals
ELDN
$264M
$1.7M 0.06%
+790
New +$1.53M
BGMS
178
Bio Green Med Solution Inc
BGMS
$4.86M
$1.68M 0.06%
2
-1
-33% -$728K
VRTX icon
179
CALL
Vertex Pharmaceuticals
VRTX
$124B
$1.67M 0.06%
135
-99
-42% -$12.5K
CLRB icon
180
Cellectar Biosciences
CLRB
$20.1M
$1.64M 0.06%
19
-3
-14% -$262K
DVAX
181
DELISTED
Dynavax Technologies
DVAX
$1.64M 0.06%
+70,000
New +$1.52M
RPRX
182
CALL
DELISTED
Repros Therapeutics Inc.
RPRX
$1.63M 0.06%
2,277
+524
+30% +$4.08K
RPTP
183
PUT
DELISTED
RAPTOR PHARMACEUTICAL CORP COM STK (DE)
RPTP
$1.63M 0.06%
+1,030
New +$12.5K
NUVA
184
CALL
DELISTED
NuVasive, Inc.
NUVA
$1.61M 0.06%
340
+206
+154% +$9.63K
CYH icon
185
CALL
Community Health Systems
CYH
$385M
$1.61M 0.06%
309
-718
-70% -$32.2K
PGEN icon
186
CALL
Precigen
PGEN
$1.99B
$1.58M 0.06%
+327
New +$13.8K
TTOO
187
DELISTED
T2 Biosystems, Inc
TTOO
$1.58M 0.06%
19
-13
-41% -$1.13M
VIRX
188
PUT
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$1.53M 0.06%
24
– –
CDMO
189
DELISTED
Avid Bioservices, Inc. Common Stock
CDMO
$1.53M 0.06%
+9,654
New +$92.8K
MNK
190
CALL
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
$1.5M 0.05%
+127
New +$15.7K
IMNN icon
191
Imunon
IMNN
$6.43M
$1.49M 0.05%
231
+147
+175% +$1.04M
OCRX
192
DELISTED
Ocera Therapeutics, Inc.
OCRX
$1.44M 0.05%
379,574
+25,000
+7% +$95.9K
MDGN.WS
193
DELISTED
MEDGENICS INC WT PUR COM EXP 03/31/16
MDGN.WS
$1.44M 0.05%
+1,439,840
New +$3.82M
PRTK
194
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$1.43M 0.05%
+55,613
New +$1.58M
ADXS
195
PUT
DELISTED
Advaxis Inc
ADXS
$1.42M 0.05%
+46
New +$14.5K
PRQR icon
196
ProQR Therapeutics
PRQR
$253M
$1.38M 0.05%
83,000
-41,380
-33% -$780K
ARIA
197
DELISTED
Ariad Pharmaceuticals Inc
ARIA
$1.37M 0.05%
165,270
-8,482
-5% -$75K
FWP
198
DELISTED
Forward Pharma A/S American Depositary Shares
FWP
$1.33M 0.05%
5,007
-7,859
-61% -$1.88M
TRUP icon
199
Trupanion
TRUP
$1.13B
$1.33M 0.05%
161,012
-78,988
-33% -$648K
ARIA
200
PUT
DELISTED
Ariad Pharmaceuticals Inc
ARIA
$1.32M 0.05%
1,599
– –
6 7
8
9 10

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q2 2015 Portfolio in Review

As of Q2 2015, Sabby Management held 404 positions worth $2.74B, up 14% from $2.4B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Sabby Management withdrew a net $310M in Q2 2015, closing 88 positions and reducing 80 holdings. Its most notable exit was Allergan plc, an estimated $33.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 8.3% of assets, down from 9.4% a quarter earlier, followed by Energy and Technology.

Against the trend, Sabby Management opened a new position in ExxonMobil worth $14.8M.

  • Sabby Management's largest Q2 2015 buy was ExxonMobil: 178,310 shares worth $14.8M.
  • Sabby Management added most to iShares 20+ Year Treasury Bond ETF in Q2 2015, an estimated $23.4M increase.
  • Sabby Management's biggest Q2 2015 reduction was Tempest Therapeutics, cutting an estimated $53.9M.
  • Sabby Management fully exited Allergan plc in Q2 2015, selling an estimated $33.8M.
  • Sabby Management's ten largest holdings make up 45% of its $2.74B portfolio in Q2 2015.
  • Sabby Management opened 120 new positions and closed 88 in Q2 2015.
  • Sabby Management's portfolio value rose 14% quarter-over-quarter to $2.74B.

Based on Sabby Management's 13F filing for Q2 2015, filed 14 Aug 2015.